HAP and VAP Treatment Guidelines

Core Microbiological Differences

Late-onset HAP and VAP (≥5 days hospitalization) are predominantly caused by MDR pathogens, including Pseudomonas aeruginosa, Acinetobacter species, methicillin-resistant Staphylococcus aureus (MRSA), and resistant Enterobacteriaceae, according to the American Thoracic Society, 1, 2
Community-acquired pneumonia is typically caused by antibiotic-sensitive organisms, including Streptococcus pneumoniae, Haemophilus influenzae, and methicillin-susceptible Staphylococcus aureus, as stated by the Infectious Diseases Society of America, 3

Antimicrobial therapy within preceding 90 days increases the risk of MDR pathogens, with an odds ratio of 13.5, as reported by the European Respiratory Society, 4, 5
Current hospitalization ≥5 days increases the risk of MDR pathogens, with an odds ratio of 6.0 for mechanical ventilation ≥7 days, according to the European Respiratory Society, 4, 5
Prior hospitalization for ≥2 days within preceding 90 days, residence in a nursing home or extended care facility, chronic dialysis within 30 days, home infusion therapy or wound care, and immunosuppressive disease or therapy are also risk factors for MDR pathogens, as stated by the Infectious Diseases Society of America, 3, 5

Attributable mortality for HAP/VAP ranges from 33-50% when caused by MDR pathogens, particularly with Pseudomonas aeruginosa or Acinetobacter bacteremia, according to the American Thoracic Society, 1, 2
Treatment with ineffective antibiotic therapy is directly associated with increased mortality, as reported by the American Thoracic Society, 1, 2
The crude mortality rate for HAP can reach 30-70%, though attributable mortality is estimated at 5-13% in general populations and up to 33-50% in ventilated patients, as stated by the Infectious Diseases Society of America, 3, 6

Empirical therapy for HAP/VAP must cover MDR pathogens, including antipseudomonal beta-lactam, antipseudomonal fluoroquinolone or aminoglycoside, and anti-MRSA coverage, as recommended by the American Thoracic Society, 1, 4
Standard regimens for CAP target susceptible organisms, including beta-lactam plus macrolide or respiratory fluoroquinolone monotherapy, as stated by the Infectious Diseases Society of America, 3

Early-onset HAP (≤4 days) still requires MDR coverage if prior antibiotics within 90 days, prior hospitalization within 90 days, or other risk factors are present, as recommended by the American Thoracic Society, 1, 2
Local antibiogram data is critical to guide specific agent selection within the broad-spectrum framework, as reported by the European Respiratory Society, 4
The HCAP designation is no longer recommended by 2016 guidelines, as many patients do not harbor MDR pathogens despite healthcare contact, according to the Infectious Diseases Society of America, 7, 4